The 35-day US government shutdown has not just played havoc at government-run agencies – it has had a knock-on effect on the stock market because of cutbacks at the Securities and Exchange
Roche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular atrophy – and the plans just got a boost after European regulators gave it speci
Eli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss biotech AC Immune, as focus shifts away from therapies targeting clumps
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.